

# Correction to Oplustilova L, et al. Cell Cycle Volume 11, Issue 20; pp. 3837–50

Lenka Oplustilova,<sup>1,2</sup> Kamila Wolanin,<sup>1</sup> Martin Mistrik,<sup>3</sup> Gabriela Korinkova,<sup>3</sup> Dana Simkova,<sup>3</sup> Jan Bouchal,<sup>3</sup> Rene Lenobel,<sup>4</sup>  
Jirina Bartkova,<sup>1</sup> Alan Lau,<sup>2</sup> Mark J. O'Connor,<sup>2</sup> Jiri Lukas<sup>1,5</sup> and Jiri Bartek<sup>1,3,\*</sup>

<sup>1</sup>Danish Cancer Society Research Center; Copenhagen, Denmark; <sup>2</sup>AstraZeneca; iMed Oncology; Macclesfield, Cheshire, UK; <sup>3</sup>Institute of Molecular and Translational Medicine; Faculty of Medicine and Dentistry; Palacky University; Olomouc, Czech Republic; <sup>4</sup>Laboratory of Growth Regulators; Palacky University Olomouc; Olomouc, Czech Republic; <sup>5</sup>Novo Nordisk Foundation Center for Protein Research; Faculty of Health and Medical Sciences; University of Copenhagen; Copenhagen, Denmark

It has come to the attention of the authors that in their Report, “Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment,” in the October 15, 2012 issue of *Cell Cycle*, an important source of funding was omitted. Dr M. Mistrik was supported by the GACR grant no. 301/11/P554.

\*Correspondence to: Jiri Bartek; Email: jiri.lukas@cpr.ku.dk  
Submitted: 06/03/13; Accepted: 06/03/13  
<http://dx.doi.org/10.4161/cc/25393>